期刊文献+

辛伐他汀联合选择性胆固醇吸收抑制剂依折麦布治疗高脂血症的临床疗效观察 被引量:1

原文传递
导出
摘要 目的观察应用选择性胆固醇吸收抑制剂依折麦布治疗高脂血症的临床疗效。方法选择高脂血症患者80例,随机分为辛伐他汀组(对照组)40例和辛伐他汀加依折麦布组(治疗组)40例,治疗8周,观察2组患者治疗前后血脂变化。结果治疗组患者血脂改善情况总有效率显著优于对照组(87.5%vs62.5%,P=0.01);2组患者治疗后TC、TG、LDL-C较治疗前显著降低,HDL-C明显升高(P均<0.05),且治疗组治疗后较对照组治疗后改善更加显著(P均<0.05)。结论应用选择性胆固醇吸收抑制剂依折麦布联合他汀类治疗高脂血症疗效显著。
出处 《中国临床研究》 CAS 2012年第3期237-238,共2页 Chinese Journal of Clinical Research
  • 相关文献

参考文献7

  • 1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5219
  • 2卫生部药政局.新药(西药)临床研究指导原则汇编[M].北京:1993.43,46
  • 3血脂康调整血脂对冠心病二级预防研究协作组.中国冠心病二级预防研究[J].中华心血管病杂志,2005,33(2):109-115. 被引量:220
  • 4Nakamura H,Arakawa K,Itakura H,et al.Primary prevention of cardiovascular disease with pravastatin in Japan(MEGA study):a propespective randomised controlled trial[J].Lancet,2006,368(9542):1155-1163.
  • 5司全金.胆固醇吸收抑制剂依折麦布的临床应用[J].中华老年心脑血管病杂志,2011,13(5):479-480. 被引量:11
  • 6Masana L,Mata P,Gagne C,et al.Long-term safety and,tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment:a multicenter,randomized,double-blind,placebo-controlled,48-week extension study[J].Clin Ther,2005,27(2):174-184.
  • 7Ballantyne CM,Abate N,Yuan Z,et al.Dose-comparison study of the combination of ezetimibe and simvastatin(Vytorin)versus atorvastain in patients with hypercholesterolemia:the Vytorin Versus Atorvastatin(VYVA)Study[J].Am Heart J,2005,149(3):464-473.

二级参考文献154

共引文献5410

同被引文献17

  • 1郑军.肠道菌群失调与脂肪肝患者血脂和丙氨酸氨基转移酶的变化研究[J].中国微生态学杂志,2007,19(2):161-162. 被引量:10
  • 2中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5219
  • 3Imes CC, Austin MA. Low-density lipoprotein cholesterol, apolipoprotein B, and risk of coronary heart disease: from familial hyperlipidemia to genomics. Biol Res Nurs 2013; 15:292-308 [PMID: 22531366 DOI: 10.1177/1099800412436967].
  • 4Peter R, Bajwa H, Anthony S. Hyperlipidaemia and cardiovascular disease -- newer antihyperglycaemic agents and cardiovascular disease. Curr Opin Lipidol 2013; 24:189-190 [PMID: 23481234 DOh 10.1097/MOL.0b0 t 3e32835ecSfS].
  • 5Kim E, Febbraio M, Bao Y, Tolhurst AT, Epstein JM, Cho S. CD36 in the periphery and brain synergizes in stroke injury in hyperlipidemia. Ann Neurol 2012; 71:753-764 [PMID: 22718544 DOI: 10.1002/ana.23569].
  • 6Tzefos M, Olin JL. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. J Clin Lipidol 2011; 5:450-459 [PMID: 22108148 DOI: 10.1016/ j.jacl.2011.06.013].
  • 7Chen D, Yang Z, Chen X, Huang Y, Yin B, Guo F, Zhao H, Zhao T, Qu H, Huang J, Wu Y, Gu R. The effect of Lactobacillus rhamnosus hsryfm 1301 on the intestinal microbiota of a hyperlipidemic rat model. BMC Complement Altern Med 2014; 14:386 [PMID: 25300818 DOI: 10.1186/1472-6882-14-386].
  • 8Tsai CC, Lin PP, Hsieh YM, Zhang ZY, Wu HC, Huang CC. Cholesterol-lowering potentials of lactic acid bacteria based on bile-salt hydrolase activity and effect of potent strains on cholesterol metabolism in vitro and in vivo.ScienticWorldJournal 2014; 2014:690752 [PMID: 25538960 DOI: 10.1155/2014/690752].
  • 9Hekmatdoost A, Feizabadi MM, Djazayery A, Mirshafiey A, Eshraghian MR, Yeganeh SM, Sedaghat R, Jacobson K. The effect of dietary oils on cecal microflora in experimental colitis in mice. Indian J Gastroenterol 2008; 27:186-189 [PMID: 19112187].
  • 10Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S, Carteni M, Nardone G. Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22:471-476 [PMID: 22546554 DOI: 10.1016/ j.numecd.2012.02.007].

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部